Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 18Completed 17Terminated 7Withdrawn 4Active not recruiting 4Unknown 2Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 8Recurrence 4Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Non-Hodgkin 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Chromosome 17 deletion 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × venetoclax × Clear all
NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Karyopharm Therapeutics Inc

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05740449 2024-06-21

HEM-iSMART A

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02095574 2014-08-13

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

AbbVie

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT01969682 2014-05-26

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

AbbVie

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡